Alpine Immune Sciences' Reverse Merger Round

Alpine Immune Sciences raised a round of funding on July 24, 2017. Investors include Nivalis Therapeutics.

Alpine Immune Sciences uses proprietary variant immunoglobulin domain (vIgD) platform technology – designed to interact with multiple targets simultaneously in the immune synapse using a single mole…

Articles about Alpine Immune Sciences' Reverse Merger Round: